Novamind Inc announces the expansion and optimization of its Cedar Psychiatry clinic in Utah.
Psychedelics
This is Why the Psilocybin Story is Quickly Gaining Momentum
Clinical studies continue to support the use of psilocybin for mental health. For example, a study from JAMA Psychiatry found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR.
ATAI or MindMed: Which Is The Better Opportunity?
ATAI Life Sciences and MindMed Inc have the deepest psychedelics operations in this sector. Which is the better opportunity?
Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy
MindCure signs LOI to make a strategic investment in ATMA, a psychedelics-assisted therapy center in Calgary, Alberta.
Cybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Pursuant to the Adelia Acquisition
Cybin announces the API synthesis of multiple tryptamine derivatives.
MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers
MindMed commences LSD microdosing study on various health-and-wellness benefits.
MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers
MindMed to Commence Groundbreaking LSD Microdosing Study Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and Immune System Response on the Human Body
Core One Labs Announces Breakthrough in Solving Psilocybin Dosing Problems by Introducing Biosynthetic Psilocybin to its Patented Thinstrip Delivery Method
Core One Labs announces a research breakthrough to help improve consistency in psilocybin dosing.
Michigan Prosecutor Won’t Pursue Most Marijuana Or Psychedelics Cases, ‘Regardless Of The Amount’
A county prosecutor in Michigan announced on Tuesday that his office will not be pursuing charges over possessing marijuana or entheogenic substances like psilocybin and ayahuasca — “regardless of the amount at issue.”
Minerco Inc the Magic Mushroom Company Appoints Health Care Consultant Paul Hoonjan as President
Oakland, California--(Newsfile Corp. - January 11, 2021) - The Magic Mushroom Company (OTCP Pink: MINE) specializing in growing, research, production and distribution of psilocybin mushrooms, announced today that Paul Hoonjan has been appointed as its new President.
KCSA Strategic Communications to Host Inaugural KCSA Psychedelics Investor Conference on January 26-27, 2021
KCSA Communications hosts an investment conference featuring Rick Doblin (MAPS) as a keynote speaker.
Airdrie cancer patient first Albertan to undergo legal magic mushroom therapy
Tony White called his therapy session powered by magic mushrooms “a good trip.”
Will ATAI IPO Be The First Major Psychedelics Catalyst For 2021?
The ATAI Life Sciences IPO could come as soon as the end of January. What does this mean for psychedelic stock investors?
MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet High Investor Demand
MindMed closes on a CAD$92.1 million financing from what was originally a $50 million offering. Total cash on hand increases to US$144.4 million.
Will psychedelic mushroom vacations come to the U. S.?
The palm-fringed beachfront and breezy cabanas at MycoMeditations are the stuff of glossy travel brochures, but the barefoot vacationers roaming the Jamaican retreat center this winter are seeking a different kind of trip entirely.